Nalaganje...

ICIs治疗晚期非小细胞肺癌免疫相关不良事件的系统综述及Meta分析

BACKGROUND AND OBJECTIVE: In recent years, immune checkpoint inhibitors (ICIs) have become a hot spot in cancer because of their remarkable survival benefits on non-small cell lung cancer (NSCLC) patients. However, the immune-related adverse events (ir-AEs) induced by ICIs have been frequently repor...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Zhongguo Fei Ai Za Zhi
Format: Artigo
Jezik:Inglês
Izdano: 中国肺癌杂志编辑部 2020
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7519956/
https://ncbi.nlm.nih.gov/pubmed/32752580
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2020.104.07
Oznake: Označite
Brez oznak, prvi označite!